Merck & Co.
MRK
$130.20
+0.32%
Merck & Co., Inc. is a global pharmaceutical leader developing innovative medicines and vaccines across oncology, infectious diseases, and cardiometabolic conditions, with its blockbuster immuno-oncology drug Keytruda driving a significant portion of sales. As a top-tier big pharma company, Merck holds a dominant position in cancer immunotherapy and pediatric vaccines, including Gardasil for HPV. The current investor narrative centers on Merck's ability to navigate the impending patent cliff for Keytruda, with recent news highlighting FDA label expansions for its pneumococcal vaccine Capvaxive and ongoing pipeline developments, while merger mania in big pharma and patent cliff risks remain key debates.…
MRK
Merck & Co.
$130.20
Related headlines
MRK 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Merck & Co.'s 12-month outlook, with a consensus price target around $135.19 and implied upside of +3.8% versus the current price.
Average Target
$135.19
0 analysts
Implied Upside
+3.8%
vs. current price
Analyst Count
—
covering this stock
Price Range
$105 - $155
Analyst target range
Merck is covered by 26 analysts, with a consensus recommendation of 'Buy' (mean rating 1.82 on a 1-5 scale). The average target price is $134.62, implying approximately 2.7% upside from the current price of $131.07. The distribution leans bullish, with no sell ratings and a majority of buy/outperform ratings. The target price range spans from a low of $100.00 to a high of $155.00. The high target of $155 assumes successful pipeline execution and Keytruda longevity, while the low target of $100 reflects risks from patent expirations and competitive pressure. Recent analyst actions have been largely positive, with firms like BMO Capital, Guggenheim, and JP Morgan reaffirming outperform/buy ratings in July 2026. The relatively tight spread between the average and high target suggests moderate conviction, while the wide low-to-high range indicates uncertainty around the post-Keytruda growth trajectory.
Drowning in data?
Find the real signal!
Bulls vs Bears: MRK Investment Factors
Merck presents a mixed investment case: strong free cash flow, high margins, and a discounted valuation are countered by the looming Keytruda patent cliff and decelerating revenue growth. The bull case rests on the stock's defensive characteristics, robust pipeline, and potential for multiple expansion as the market underestimates Merck's ability to navigate patent expirations. The bear case emphasizes the risk of revenue erosion and the Q1 net loss highlighting development costs. Currently, the evidence slightly favors the bull case given the attractive valuation and strong cash flows, but the Keytruda cliff remains the single most important tension—its resolution will determine whether Merck can sustain its current valuation or face a de-rating.
Bullish
- Strong Free Cash Flow Generation: Merck generated $14.1 billion in free cash flow over the trailing twelve months, providing ample liquidity for dividends, share buybacks, and strategic acquisitions. This robust cash flow supports a sustainable dividend yield of 3.1% and a payout ratio of 44.8%.
- Attractive Valuation vs. Peers: The trailing P/E of 14.4x and forward P/E of 13.6x represent a ~20% discount to the industry median of 18x. This discount is unjustified given Merck's strong free cash flow and pipeline, suggesting potential for multiple expansion.
- Strong Momentum and Relative Strength: The stock is up 55.8% over the past year, significantly outperforming the S&P 500's 16.5% gain. Relative strength over 1-month, 3-month, and 6-month periods is positive, indicating sustained investor confidence.
- Robust Gross Margin and ROE: Gross margin remains high at 81.9% in Q1 2026, and ROE is an impressive 34.7%, reflecting strong profitability and efficient capital use. These metrics underscore Merck's competitive advantages in branded pharmaceuticals.
Bearish
- Keytruda Patent Cliff Looms: Keytruda, Merck's top-selling drug, faces patent expirations later this decade, which could lead to significant revenue erosion from biosimilar competition. This overhang is a primary reason for the valuation discount relative to peers.
- Q1 2026 Net Loss Due to R&D Charge: Merck reported a net loss of -$4.24 billion in Q1 2026 due to a massive $12.56 billion R&D charge, resulting in negative operating margin of -11.6%. While non-recurring, such charges highlight the high-risk nature of drug development.
- Revenue Growth Deceleration: Q1 2026 revenue growth of 4.3% YoY decelerated from 8.5% in Q3 2025, signaling potential maturation of Keytruda and other key products. Slowing top-line growth could pressure the stock's premium valuation.
- High Debt-to-Equity Ratio: Debt-to-equity stands at 0.96, relatively high for a pharmaceutical company. While manageable given strong cash flows, elevated leverage increases financial risk, especially if earnings decline post-patent cliff.
MRK Technical Analysis
Merck is in a sustained uptrend, with the stock up 55.8% over the past year, significantly outperforming the S&P 500's 16.5% gain. The current price of $131.07 sits at 99.5% of its 52-week range (high $131.74, low $76.66), indicating strong momentum and near all-time highs, which suggests bullish sentiment but also potential overextension. Short-term momentum is accelerating: the 1-month return is +8.7% and the 3-month return is +17.1%, both outpacing the S&P 500's 0.8% and 3.5% respectively. This divergence from the broader market signals strong relative strength, with the 1-month relative strength at +7.9% and 3-month at +13.6%. The stock's beta of 0.205 indicates it is significantly less volatile than the market, making it a defensive holding. Key support lies at the 52-week low of $76.66, while resistance is at the 52-week high of $131.74. A breakout above $131.74 would signal a continuation of the uptrend, while a breakdown below recent support near $120 could indicate a pullback.
Beta
0.20
0.20x market volatility
Max Drawdown
-11.9%
Largest decline past year
52-Week Range
$78-$135
Price range past year
Annual Return
+66.7%
Cumulative gain past year
| Period | MRK Return | S&P 500 |
|---|---|---|
| 1m | +3.9% | +0.2% |
| 3m | +16.1% | +3.7% |
| 6m | +18.1% | +8.0% |
| 1y | +66.7% | +18.2% |
| ytd | +22.3% | +9.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MRK Fundamental Analysis
Merck's revenue trajectory is growing, with Q1 2026 revenue of $16.29 billion up 4.3% year-over-year, though this decelerates from the 8.5% growth seen in Q3 2025 ($17.18 billion). The pharmaceutical segment, which generated $14.35 billion in Q1 2026, remains the primary growth driver, while the animal health segment contributed $1.79 billion. The company reported a net loss of -$4.24 billion in Q1 2026 due to a large R&D charge, but on a trailing twelve-month basis, net income was positive. Gross margin remains strong at 81.9% in Q1 2026, though down from 75.6% in Q2 2025, reflecting product mix shifts. Operating margin turned negative at -11.6% in Q1 2026 due to the R&D charge, but normalized margins are healthy. Merck's balance sheet is solid: debt-to-equity is 0.96, and the current ratio is 1.54, indicating adequate liquidity. Free cash flow over the trailing twelve months was $14.1 billion, providing ample cash for dividends and acquisitions. ROE is robust at 34.7%, reflecting strong profitability, while the payout ratio of 44.8% supports a sustainable dividend yield of 3.1%.
Quarterly Revenue
$16.3B
2026-03
Revenue YoY Growth
+4.3%
YoY Comparison
Gross Margin
81.9%
Latest Quarter
Free Cash Flow
$14.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MRK Overvalued?
Since net income is positive on a trailing basis (TTM net income of $9.9 billion), the primary valuation metric is the P/E ratio. The trailing P/E is 14.4x, while the forward P/E is 13.6x, implying the market expects modest earnings growth. The gap between trailing and forward P/E suggests a slight expansion in earnings expectations. Compared to the industry average (Drug Manufacturers - General), Merck's P/E of 14.4x is at a discount to the sector median of approximately 18x, representing a 20% discount. This discount may be justified by the looming Keytruda patent cliff and recent R&D charges, but Merck's strong free cash flow and pipeline could warrant a premium. Historically, Merck's trailing P/E has ranged from 9x to 24x over the past five years. The current 14.4x is near the lower end of its historical range, suggesting the stock is undervalued relative to its own history, potentially offering a value opportunity if growth stabilizes.
PE
14.4x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 9x~32x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
10.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Merck's Q1 2026 net loss of -$4.24 billion, driven by a $12.56 billion R&D charge, underscores the high cost and volatility of pharmaceutical R&D. While the company generated $14.1 billion in free cash flow over the TTM, the debt-to-equity ratio of 0.96 indicates moderate leverage. Revenue growth decelerated to 4.3% YoY in Q1 2026 from 8.5% in Q3 2025, suggesting potential maturation of key products. The payout ratio of 44.8% is sustainable, but any prolonged earnings decline could pressure the dividend.
Market & Competitive Risks: Merck's beta of 0.205 makes it a defensive holding with low market correlation, but the stock is trading near its 52-week high, leaving limited upside from current levels. The industry median P/E of 18x implies Merck's 14.4x trailing P/E is a 20% discount, which may reflect the market's skepticism about post-Keytruda growth. Competitive threats include biosimilars for Keytruda and rival vaccines from Pfizer. Recent news highlights merger mania in big pharma, but Merck's patent cliff risks could make it a target rather than an acquirer.
Worst-Case Scenario: If Keytruda faces accelerated biosimilar competition and pipeline candidates fail to offset revenue declines, Merck's earnings could contract significantly. The analyst low target of $100 implies a potential 23.7% downside from the current price of $131.07. The 52-week low of $76.66 represents a 41.5% decline, which could occur in a severe recession or major pipeline failure. In such a scenario, an investor could lose up to -41.5% from the current price.
